Scholarlink

<p>The development of effective and low-toxicity treatments for type 2 diabetes mellitus (T2DM) remains a critical objective in current research. Lactic acid bacteria (LAB) fermentation can biotransform plant polysaccharides and may enhance their bioactivity. Here, we investigated the fermentation with <i>Limosilactobacillus reuteri</i> DSM17938 fermentation affects the structure of <i>Gastrodia elata</i> polysaccharides and their potentail benefits in T2DM. Polysaccharides were extracted from non-fermented <i>G. elata</i> (GP) and from <i>G. elata</i> fermented with <i>L. reuteri</i> DSM 17,938 under controlled conditions to yield fermented polysaccharides (LGP). Fermentation reduced molecular weight and shifted monosaccharide composition, including increased content of galactose, arabinose, glucose, xylose, and galacturonic acid while decreased content of fructose. Fermentation reduced the molecular weight, altered the morphology, and shifted the monosaccharide composition, including increased content of arabinose and galacturonic acid while decreasing fructose. In a T2DM mouse model, LGP (10.9 ± 0.8 mmol/L) demonstrated a more significant hypoglycemic effect compared to GP (14.6 ± 1.4 mmol/L, <i>p</i> &lt; 0.001). Furthermore, LGP more effectively improved antioxidant and inflammatory profiles markers (<i>p</i> &lt; 0.001), and attenuated intestine and kidney injury. Mechanistic investigations revealed that LGP modulates gut microbiota composition by reducing the Firmicutes/Bacteroidetes ratio and promoting the proliferation of beneficial bacteria such as <i>Kineothrix</i> and <i>Akkermansia</i>, while concurrently increasing short-chain fatty acid levels and regulating serum metabolic pathways related to carbohydrate and protein digestion and absorption. This study demonstrates that LAB fermentation is an effective bioprocessing strategy for enhancing the hypoglycemic activity of GPs, offering novel insights for the production of functional foods.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Limosilactobacillus reuteri fermentation enhances the anti-type 2 diabetic activity of Gastrodia elata polysaccharides

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年1月18日

查看全文
  • Jiajia Liu,
  • Zongyang Li,
  • Shixiao Pu,
  • Xing Huang,
  • Zixian Xu,
  • Xiaoqi Yang,
  • Yunlong Zhang,
  • Chengying Luo,
  • Shibo Li,
  • Jiayun Miao,
  • Yicen Lin,
  • Lianbing Lin

摘要

The development of effective and low-toxicity treatments for type 2 diabetes mellitus (T2DM) remains a critical objective in current research. Lactic acid bacteria (LAB) fermentation can biotransform plant polysaccharides and may enhance their bioactivity. Here, we investigated the fermentation with Limosilactobacillus reuteri DSM17938 fermentation affects the structure of Gastrodia elata polysaccharides and their potentail benefits in T2DM. Polysaccharides were extracted from non-fermented G. elata (GP) and from G. elata fermented with L. reuteri DSM 17,938 under controlled conditions to yield fermented polysaccharides (LGP). Fermentation reduced molecular weight and shifted monosaccharide composition, including increased content of galactose, arabinose, glucose, xylose, and galacturonic acid while decreased content of fructose. Fermentation reduced the molecular weight, altered the morphology, and shifted the monosaccharide composition, including increased content of arabinose and galacturonic acid while decreasing fructose. In a T2DM mouse model, LGP (10.9 ± 0.8 mmol/L) demonstrated a more significant hypoglycemic effect compared to GP (14.6 ± 1.4 mmol/L, p < 0.001). Furthermore, LGP more effectively improved antioxidant and inflammatory profiles markers (p < 0.001), and attenuated intestine and kidney injury. Mechanistic investigations revealed that LGP modulates gut microbiota composition by reducing the Firmicutes/Bacteroidetes ratio and promoting the proliferation of beneficial bacteria such as Kineothrix and Akkermansia, while concurrently increasing short-chain fatty acid levels and regulating serum metabolic pathways related to carbohydrate and protein digestion and absorption. This study demonstrates that LAB fermentation is an effective bioprocessing strategy for enhancing the hypoglycemic activity of GPs, offering novel insights for the production of functional foods.